The Nasdaq Golden Dragon China Index closed up 0.31% at 6,806.82 points, rising 0.83% for the week, with a significant gap-up opening on April 8.

Recorded an eight-day consecutive rise

Replimune's skin cancer drug is rejected again by the US FDA, causing the company's stock price to plummet

Propanc Biopharma has filed documents with the U.S. Securities and Exchange Commission regarding a reselling plan of common shares initiated by selling shareholders.

This week, non-U.S. currencies generally strengthened, with the euro up 1.8%, the New Zealand dollar up 2.6%, and the Hungarian forint rising by more than 4.3%.